Table 1.
Preparation | Methods of administration (dosing regime) | ||
---|---|---|---|
Repeated low dose and bolus administration | Intravenous drip | Intravenous drip | |
Moderate dose infusion | Total dose infusions | ||
(100–510 mg) | (200–1000 mg) | > 1000 mg | |
Low-molecular-weight iron dextran (Cosmofer) | ≤ 200 mg | ≤ 1000 mg | 1500 mg ~ 4–6 h (3 ha), Up to 20 mg iron/kg ~ 4–6 h + test dose |
Iron sucrose (Venofer) | ≤ 200 mg | ≤ 200 mg | Not applicable |
Iron gluconate (Ferelecit) | 125 mg | Not applicable | Not applicable |
Iron isomaltoside 1000 (Monofer) | ≤ 200 mg | ≤ 1000 mg not exceeding 20 mg iron/kg | 1000–2000 mg ~ 1 h |
0–10 mg iron/kg ~ 30 min | |||
11–20 mg iron/kg ~ 60 min | |||
Iron carboxymaltose (Ferinject) | ≤ 200 mg | ≤ 1000 mg not exceeding 15 mg iron/kg | Not applicable |
Feraheme (ferumoxytol) | = 510 mg | 510 mg | Not applicable |
aAccelerated dose infusion regime used by the author and several other units—Sinha S, Chiu D, Peebles G, Fenwick S, Bhandari S, Kalra P. Accelerated total dose infusion of low-molecular-weight iron dextran is safe and efficacious in chronic kidney disease patients. Quarterly Journal of Medicine, Advanced access published 18 October 2010